Driehaus Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Driehaus Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-5,403	Closed	-$3.03M	–	521
2014 Q4	$3.03M	Buy	5,403 +146	+3%	+$82.9K	0.12%	227
2014 Q3	$2.75M	Buy	5,257 +136	+3%	+$76.8K	0.11%	257
2014 Q2	$3.58M	Buy	5,121 +559	+12%	+$260K	0.12%	240
2014 Q1	$2.11M	Sell	4,562 -1,452	-24%	-$736K	0.07%	324
2013 Q4	$2.07M	Buy	+6,014	New	+$1.66M	0.07%	306

Other funds holding KPTI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Driehaus Capital Management's KPTI Position: Q1 2015 in Review

Driehaus Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2015, closing a stake of 5,403 shares — an estimated $3.03M sold.

Driehaus Capital Management first reported a position in KPTI in Q4 2013 and held it in 5 quarters. The position peaked at $3.58M in Q2 2014. 85 funds tracked by Wall St. Rank hold KPTI as of Q1 2015.

Driehaus Capital Management reported no remaining Karyopharm Therapeutics position as of Q1 2015 after selling out during the quarter.
Driehaus Capital Management sold 5,403 Karyopharm Therapeutics shares in Q1 2015, an estimated $3.03M.
Driehaus Capital Management first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 5 quarters.
Driehaus Capital Management's Karyopharm Therapeutics position peaked at $3.58M in Q2 2014.
85 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2015.

Based on Driehaus Capital Management's 13F filing for Q1 2015, filed 15 May 2015.